MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

183.22 -1.45

Visão Geral

Variação de preço das ações

24h

Atual

Mín

181.97

Máximo

189.67

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+6.34% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

859M

8.8B

Abertura anterior

184.67

Fecho anterior

183.22

Sentimento de Notícias

By Acuity

7%

93%

11 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de abr. de 2026, 23:49 UTC

Notícias Principais

New Zealand 1Q Inflation Higher Than Expected

20 de abr. de 2026, 23:10 UTC

Ações em Alta

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20 de abr. de 2026, 22:53 UTC

Grandes Movimentos do Mercado

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20 de abr. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20 de abr. de 2026, 23:44 UTC

Conversa de Mercado

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20 de abr. de 2026, 23:39 UTC

Conversa de Mercado

Rio Tinto Posts Strong Start to Year -- Market Talk

20 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20 de abr. de 2026, 23:09 UTC

Conversa de Mercado

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20 de abr. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 de abr. de 2026, 22:26 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Aims for Acquisition to Be Completed by End-2026

20 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Says Acquisition Would Be for A$175 Million

20 de abr. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20 de abr. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 de abr. de 2026, 22:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20 de abr. de 2026, 21:38 UTC

Conversa de Mercado

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20 de abr. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20 de abr. de 2026, 21:24 UTC

Conversa de Mercado

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20 de abr. de 2026, 21:24 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de abr. de 2026, 21:13 UTC

Ganhos

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20 de abr. de 2026, 21:10 UTC

Ganhos

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20 de abr. de 2026, 21:09 UTC

Ganhos

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20 de abr. de 2026, 21:08 UTC

Ganhos

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20 de abr. de 2026, 21:07 UTC

Ganhos

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20 de abr. de 2026, 21:05 UTC

Ganhos

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20 de abr. de 2026, 21:05 UTC

Ganhos

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

6.34% parte superior

Previsão para 12 meses

Média 197.3 USD  6.34%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

11 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat